URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer
Information about Gemfibrozil
Clofibrate is a fibric acid derivative used in the therapy of hypertriglyceridemia and dyslipidemia.
Liver safety of Gemfibrozil
Mechanism of action of Gemfibrozil
Clofibrate (kloe fye' brate) is a fibric acid derivative. The lipid lowering activity of clofibrate is probably mediated by its interactions with the peroxisome proliferator activated receptor alpha (PPARα), which regulates gene expression of enzymes involved in fatty acid oxidation. Clofibrate increases lipoprotein lipase levels which enhances clearance of triglyceride rich lipoproteins.
Dosage and administration for Gemfibrozil
Clofibrate was available for many years and frequently used in the therapy of hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia) and hypercholesterolemia (Fredrickson types IIa and IIb).
The drug Gemfibrozil was withdrawn from the US market
Use of clofibrate decreased with the availability of statins for therapy of hyperlipidemia and subsequently it was withdrawn from use in 2002. Clofibrate was available previously in generic forms and under the brand name of Atromid-S as capsules of 500 mg. The recommended dosage was 2 grams daily in divided doses.
Side effects of Gemfibrozil
Lipid lowering medications
- Niacin (Nicotinic Acid)